Related Experiment Video
Updated: Dec 4, 2025
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG
Ilango Balakrishnan1, Etienne Danis1, Angela Pierce2
1Department of Pediatrics and Section of Pediatric Hematology/Oncology/BMT, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA; The Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, CO, USA.
Abstract:
Diffuse intrinsic pontine glioma (DIPG) is an incurable brain tumor of childhood characterized by histone mutations at lysine 27, which results in epigenomic dysregulation. There has been a failure to develop effective treatment for this tumor. Using a combined RNAi and chemical screen targeting epigenomic regulators, we identify the polycomb repressive complex 1 (PRC1) component BMI1 as a critical factor for DIPG tumor maintenance in vivo. BMI1 chromatin occupancy is enriched at genes associated with differentiation and tumor suppressors in DIPG cells. Inhibition of BMI1 decreases cell self-renewal and attenuates tumor growth due to induction of senescence. Prolonged BMI1 inhibition induces a senescence-associated secretory phenotype, which promotes tumor recurrence. Clearance of senescent cells using BH3 protein mimetics co-operates with BMI1 inhibition to enhance tumor cell killing in vivo.
Insights
Researchers identified BMI1 as a key factor in diffuse intrinsic pontine glioma (DIPG) maintenance. Inhibiting BMI1 and clearing senescent cells shows promise for treating this childhood brain tumor.
Area of Science:
- Oncology
- Epigenetics
- Pediatric Cancer Research
Background:
- Diffuse intrinsic pontine glioma (DIPG) is an aggressive childhood brain tumor with no effective treatments.
- Histone mutations (H3K27) in DIPG lead to widespread epigenomic dysregulation.
- Targeting epigenomic regulators is a potential therapeutic strategy for DIPG.
Purpose of the Study:
- To identify critical factors for DIPG tumor maintenance.
- To evaluate BMI1 as a therapeutic target in DIPG.
- To explore combination strategies for enhancing DIPG treatment.
Main Methods:
- Conducted a combined RNAi and chemical screen targeting epigenomic regulators.
- Assessed BMI1 chromatin occupancy in DIPG cells.
- Inhibited BMI1 in DIPG models and evaluated tumor growth, senescence, and recurrence.
- Utilized BH3 mimetics to clear senescent cells in combination with BMI1 inhibition.
Main Results:
- Identified BMI1, a Polycomb Repressive Complex 1 (PRC1) component, as essential for DIPG maintenance in vivo.
- BMI1 is enriched at differentiation and tumor suppressor genes in DIPG.
- BMI1 inhibition reduced self-renewal and tumor growth by inducing senescence.
- Prolonged BMI1 inhibition led to a senescence-associated secretory phenotype, promoting tumor recurrence.
- Co-inhibition of BMI1 and clearance of senescent cells enhanced tumor cell killing.
Conclusions:
- BMI1 is a critical therapeutic target for DIPG.
- Targeting BMI1 induces senescence, but combination therapy is needed to overcome recurrence.
- Combining BMI1 inhibition with senescent cell clearance offers a promising strategy for DIPG treatment.
More Related Videos
10:58Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
Related Concept Videos
02:23Abnormal Proliferation
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...